The tumour microenvironment: A novel target for cancer therapy

E. Hanna, J. Quick, S. K. Libutti

Research output: Contribution to journalArticle

50 Citations (Scopus)

Abstract

Cancer therapy is in the midst of a major paradigm shift. Traditionally, cancer treatments have focused on tumour cells. However, studies over the past few decades have demonstrated that cancer is a vastly complex entity with multiple components affecting a tumour's growth, invasion and metastasis. These components, collectively termed the 'tumour microenvironment', include endothelial cells, pericytes, fibroblasts, inflammatory cells, leucocytes and elements of the extracellular matrix (ECM). Biological agents that target components of the tumour microenvironment may provide an interesting alternative to traditional tumour cell-directed therapy. Because of the complexity of the tumour milieu, the most beneficial therapy will likely involve the combination of one or more agents directed at this new target. This review highlights recent preclinical and clinical studies involving agents that target tumour vasculature, leucocytes, pericytes, cancer-associated fibroblasts and ECM components. We pay particular attention to combination therapies targeting multiple components of the tumour microenvironment, and aim to demonstrate that this strategy holds promise for the future of cancer treatment.

Original languageEnglish (US)
Pages (from-to)8-17
Number of pages10
JournalOral Diseases
Volume15
Issue number1
DOIs
StatePublished - Jan 2009
Externally publishedYes

Fingerprint

Tumor Microenvironment
Neoplasms
Pericytes
Therapeutics
Extracellular Matrix
Leukocytes
Biological Factors
Cell- and Tissue-Based Therapy
Endothelial Cells
Fibroblasts
Neoplasm Metastasis

Keywords

  • Combination therapy
  • Endothelial cells
  • Extracellular matrix
  • Fibroblasts
  • Leucocytes
  • Tumour microenvironment

ASJC Scopus subject areas

  • Dentistry(all)
  • Otorhinolaryngology

Cite this

The tumour microenvironment : A novel target for cancer therapy. / Hanna, E.; Quick, J.; Libutti, S. K.

In: Oral Diseases, Vol. 15, No. 1, 01.2009, p. 8-17.

Research output: Contribution to journalArticle

Hanna, E. ; Quick, J. ; Libutti, S. K. / The tumour microenvironment : A novel target for cancer therapy. In: Oral Diseases. 2009 ; Vol. 15, No. 1. pp. 8-17.
@article{91fcdbb9329b4ee680abc080593b0b31,
title = "The tumour microenvironment: A novel target for cancer therapy",
abstract = "Cancer therapy is in the midst of a major paradigm shift. Traditionally, cancer treatments have focused on tumour cells. However, studies over the past few decades have demonstrated that cancer is a vastly complex entity with multiple components affecting a tumour's growth, invasion and metastasis. These components, collectively termed the 'tumour microenvironment', include endothelial cells, pericytes, fibroblasts, inflammatory cells, leucocytes and elements of the extracellular matrix (ECM). Biological agents that target components of the tumour microenvironment may provide an interesting alternative to traditional tumour cell-directed therapy. Because of the complexity of the tumour milieu, the most beneficial therapy will likely involve the combination of one or more agents directed at this new target. This review highlights recent preclinical and clinical studies involving agents that target tumour vasculature, leucocytes, pericytes, cancer-associated fibroblasts and ECM components. We pay particular attention to combination therapies targeting multiple components of the tumour microenvironment, and aim to demonstrate that this strategy holds promise for the future of cancer treatment.",
keywords = "Combination therapy, Endothelial cells, Extracellular matrix, Fibroblasts, Leucocytes, Tumour microenvironment",
author = "E. Hanna and J. Quick and Libutti, {S. K.}",
year = "2009",
month = "1",
doi = "10.1111/j.1601-0825.2008.01471.x",
language = "English (US)",
volume = "15",
pages = "8--17",
journal = "Oral Diseases",
issn = "1354-523X",
publisher = "Wiley-Blackwell",
number = "1",

}

TY - JOUR

T1 - The tumour microenvironment

T2 - A novel target for cancer therapy

AU - Hanna, E.

AU - Quick, J.

AU - Libutti, S. K.

PY - 2009/1

Y1 - 2009/1

N2 - Cancer therapy is in the midst of a major paradigm shift. Traditionally, cancer treatments have focused on tumour cells. However, studies over the past few decades have demonstrated that cancer is a vastly complex entity with multiple components affecting a tumour's growth, invasion and metastasis. These components, collectively termed the 'tumour microenvironment', include endothelial cells, pericytes, fibroblasts, inflammatory cells, leucocytes and elements of the extracellular matrix (ECM). Biological agents that target components of the tumour microenvironment may provide an interesting alternative to traditional tumour cell-directed therapy. Because of the complexity of the tumour milieu, the most beneficial therapy will likely involve the combination of one or more agents directed at this new target. This review highlights recent preclinical and clinical studies involving agents that target tumour vasculature, leucocytes, pericytes, cancer-associated fibroblasts and ECM components. We pay particular attention to combination therapies targeting multiple components of the tumour microenvironment, and aim to demonstrate that this strategy holds promise for the future of cancer treatment.

AB - Cancer therapy is in the midst of a major paradigm shift. Traditionally, cancer treatments have focused on tumour cells. However, studies over the past few decades have demonstrated that cancer is a vastly complex entity with multiple components affecting a tumour's growth, invasion and metastasis. These components, collectively termed the 'tumour microenvironment', include endothelial cells, pericytes, fibroblasts, inflammatory cells, leucocytes and elements of the extracellular matrix (ECM). Biological agents that target components of the tumour microenvironment may provide an interesting alternative to traditional tumour cell-directed therapy. Because of the complexity of the tumour milieu, the most beneficial therapy will likely involve the combination of one or more agents directed at this new target. This review highlights recent preclinical and clinical studies involving agents that target tumour vasculature, leucocytes, pericytes, cancer-associated fibroblasts and ECM components. We pay particular attention to combination therapies targeting multiple components of the tumour microenvironment, and aim to demonstrate that this strategy holds promise for the future of cancer treatment.

KW - Combination therapy

KW - Endothelial cells

KW - Extracellular matrix

KW - Fibroblasts

KW - Leucocytes

KW - Tumour microenvironment

UR - http://www.scopus.com/inward/record.url?scp=57549092526&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=57549092526&partnerID=8YFLogxK

U2 - 10.1111/j.1601-0825.2008.01471.x

DO - 10.1111/j.1601-0825.2008.01471.x

M3 - Article

C2 - 18992016

AN - SCOPUS:57549092526

VL - 15

SP - 8

EP - 17

JO - Oral Diseases

JF - Oral Diseases

SN - 1354-523X

IS - 1

ER -